Pharmacy Services Alerts
Midazolam Injection 2 mg/2 mL Prefilled Syringe Mislabeling
Nov 20, 2017 9:39 AM
**Due to an update in May 2019 to the FDA.gov website, provided links may not appropriately redirect. Please visit www.fda.gov/drugs/drug-safety-and-availability to see the most recent FDA Medication Safety Alerts and Safety Communications or to search for specific alerts or communications.**
Fresenius Kabi USA is recalling midazolam injection 2 mg/2 mL prefilled syringes due to mislabeling concerns. This recall affects a single lot (6400048), which contains syringes of ondansetron injection 4 mg/2 mL, but is labeled as midazolam injection 2 mg/2 mL. If an individual misses a dose of midazolam, ineffective sedation or increased anxiety associated with a procedure may occur. If an individual receives a pre-operative dose of ondansetron, and then mistakenly receives an additional dose of ondansetron, serious adverse effects may occur, including cardiac arrhythmias and serotonin syndrome. No adverse events connected to this recall have been reported to Fresenius Kabi.
- MedWatch Safety Alert – November 03, 2017
- Fresenius Kabi USA press release – November 03, 2017